Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | HRH2 | P25021 | 2/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | DRD3 | P35462 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.72 |
| ▸ | TEK | Q02763 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efletirizine SCHEMBL3882700 | 0.99 | HRH1 (0.73) | HRH1TDP1HRH2HTR2ADRD3 | |
| Efletirizine SCHEMBL1691233 | 0.99 | HRH1 (0.73) | HRH1TDP1HRH2HTR2ADRD3 | |
| Efletirizine SCHEMBL8211713 | 0.99 | HRH1 (0.71) | HRH1TDP1HRH2HTR2ADRD3 | |
| Efletirizine SCHEMBL3874525 | 0.97 | HRH1 (0.71) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL10932667 | 0.97 | HRH1 (0.69) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL2058738 | 0.96 | HRH1 (0.79) | HRH1TDP1HRH2HTR2ADRD3 | |
| Water SCHEMBL10930897 | 0.95 | HRH1 (0.77) | HRH1TDP1HRH2HTR2ADRD3 | |
| Efletirizine SCHEMBL5794933 | 0.92 | HRH1 (0.65) | HRH1TDP1HRH2HTR2ADRD3 | |
| Efletirizine SCHEMBL5797969 | 0.92 | HRH1 (0.65) | HRH1TDP1HRH2HTR2ADRD3 | |
| Efletirizine SCHEMBL5794985 | 0.89 | HRH1 (0.61) | HRH1TDP1HRH2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1872 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111012734-B | Drug-loaded reticular in-situ phase-change gel sustained-release system and preparation method thereof | 四川大学 | 2021-08-20 | — | — | CN | claimed |
| EP-3400971-B1 | ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2021-08-04 | — | — | EP | claimed |
| EP-3400969-B1 | IMPLANTED DEVICE | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2021-05-19 | — | — | EP | claimed |
| CN-110876711-B | Method for preparing multilayer polymer microneedle | 北京化工大学 | 2021-03-26 | — | — | CN | claimed |
| US-10946121-B2 | Absorbable iron-based alloy implantable medical device | BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) | 2021-03-16 | — | — | US | claimed |
| EP-3400970-B1 | ABSORBABLE IRON-BASED ALLOY MEDICAL DEVICE IMPLANT | LIFETECH SCIENT SHENZHEN CO (CN) | 2021-03-03 | — | — | EP | claimed |
| CN-107049932-B | Small molecule drug in-situ phase change gel sustained release system and preparation method thereof | 四川大学 | 2020-11-06 | — | — | CN | claimed |
| US-20200215237-A1 | ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE | BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) | 2020-07-09 | — | — | US | claimed |
| EP-3643298-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | Sichuan University (CN) | 2020-04-29 | — | — | EP | claimed |
| CN-106806938-B | Absorbable iron-based alloy implantation medical instrument | 先健科技(深圳)有限公司 | 2020-04-14 | — | — | CN | claimed |
| US-6103735-A | IN COMBINATION, ANTAGONISTS OF A NEUORKININ, A HISTAMINE 3 AND A HISTAMINE 1; ANTIALLERGENS; RHINITIS, ASTHMA AND RELATED DISORDERS; COUGH, WHEEZING; SNEEZING, ITCHING, RUNNY NOSE, NASAL CONGESTION, REDNESS OF THE EYE, TEARING | SCHERING CORPORATION (US) | 2000-08-15 | — | — | US | claimed |
| WO-2000021512-A2 | COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES | SCHERING CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| CN-1250371-A | Pharmaceutical composition for the controlled release of active substances | UCB SA (BE) | 2000-04-12 | — | — | CN | claimed |
| CN-1233179-A | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists | SCHERING CORP (US) | 1999-10-27 | — | — | CN | claimed |
| WO-1999032125-A1 | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES, COMPRISING AT LEAST ONE LEUKOTRIENE ANTAGONIST AND AT LEAST ONE ANTIHISTAMINE | SCHERING CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0920315-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1999015203-A1 | USE OF COMBINATIONS COMPRISING NON-SEDATING ANTIHISTAMINES AND ALPHA-ADRENERGIC DRUGS FOR THE TOPICAL TREATMENT OF RHINITIS/CONJUNCTIVITIS AND COLD, COLD-LIKE AND/OR FLU SYMPTOMS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-04-01 | — | — | WO | claimed |
| EP-0903151-A1 | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms | ASTA Medica Aktiengesellschaft (DE) | 1999-03-24 | — | — | EP | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |